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Abstract In order to determine whether dimers of dopamine D2
receptors can occur in mammalian brain, rat and human brain
striatal membranes were photolabelled with two radioactive
photoaffinity compounds selective for dopamine D2 receptors,
[125I]azidophenethylspiperone and [125I]-4-azido-5-iodonemona-
pride. It was found that [125I]azidophenethylspiperone only
labelled the D2 monomer, while [125I]-4-azido-5-iodonemona-
pride labelled both D2 monomers and dimers, despite the fact
that very high concentrations (6 nM) of both radiocompounds
were used. In addition, human cloned D2 receptors were probed
with a D2-specific antibody, revealing multiple bands indicating
the existence of trimers, tetramers and pentamers of D2
receptors. The different D2-binding patterns of the spiperone
and benzamide congeners may explain the different densities of
dopamine D2 receptors found with these two radioligands in
human brain positron tomography in health and disease.
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1. Introduction
In measuring brain neurotransmitter receptors in patients
by means of positron tomography, a long-standing problem
has been the fact that two di¡erent radioligands yield signi¢-
cantly di¡erent densities for the same receptor. The problem is
further compounded when the receptor is measured in disease.
For example, the density of brain dopamine D2 receptors in
healthy volunteers is 15^16.7 pmol/ml when measured with
[11C]methylspiperone [1,2], but, even in the same laboratory
[3], is 25 pmol/ml when measured with [11C]raclopride. Farde
et al. have also found a di¡erence in these radioligand den-
sities in healthy subjects [4,5] and in schizophrenia patients
[5,6]. An analogous situation occurs in vitro in a variety of
tissues, including cloned dopamine receptors [7^10]. Such dis-
crepancy revealed by the two radioligands may be clinically
important in studying the dopamine hypothesis of schizophre-
nia, because one research team ¢nds D2 receptors to be ele-
vated in schizophrenia when using [11C]methylspiperone [1,2],
while another research team ¢nds no elevation in D2 receptors
when using [11C]raclopride [4,6]. The discrepancy suggests
that the two radioligands may bind di¡erently to the D2 re-
ceptor. We here o¡er a partial explanation by showing that
D2 receptors can exist either as monomers or dimers in mam-
malian brain tissue, with radiospiperone labelling the mono-
mer, while radionemonapride labels both forms of D2, a sit-
uation similar to that for cloned D2 receptors which we have
reported previously to exist in monomer and dimer forms [11^
13].
2. Materials and methods
2.1. Preparation of rat striatum tissue
Frozen rat brains were purchased (Pel-Freez Biologicals, Rogers,
AR, USA), thawed, and the striata removed. A total of 18 pmol of
D2 receptors was prepared from 25 frozen rat brains. (The D2 recep-
tor density in rat striatum is V30 pmol per gram of original striatum
[7,8].) The tissue was suspended in 1 ml of 0.25 M sucrose in bu¡er
(5 mM Tris-HCl, pH 7.6, 0.5 mM MgCl2, and 2 Wl of protease in-
hibitor mixture (Boehringer Mannheim, Laval, QueŁ., Canada) per ml
of bu¡er), and homogenized in 10 up-and-down strokes, using a
Te£on-glass hand homogenizer (2 ml). A crude enrichment of striatal
synaptosomes was prepared as follows. The homogenate was centri-
fuged for 5 min at 280Ug. The supernatant was saved, while the pellet
was resuspended in 1 ml of 0.25 M sucrose in bu¡er and recentrifuged
for 5 min at 280Ug. The ¢rst and second supernatants were combined
and centrifuged for 10 min at 1500Ug. The resulting pellet was re-
suspended in 1.46 M sucrose in bu¡er. Two aliquots of 30 ml each
were placed in 40-ml Beckman polyallomer centrifuge tubes and over-
laid with 7 ml of 0.25 M sucrose in bu¡er. After centrifugation at
24 000Ug for 60 min, the material at the interface of the sucrose
gradient was collected, using a blunt-tipped Pasteur pipette, and re-
suspended in 0.43 M sucrose in bu¡er. The suspension was centri-
fuged at 1500Ug for 10 min. The ¢nal pellet was resuspended in
0.25 M sucrose in bu¡er. All procedures were done at 4‡C.
2.2. Preparation of post-mortem human brain caudate nucleus tissue
Frozen samples of post-mortem human brain caudate nucleus were
obtained from the Canadian Brain Tissue Bank (CBTB). The tissues
provided were from patients CBTB 355 and CBTB 1271, both of
whom had Alzheimer’s disease. Patient CBTB 355 developed Alz-
heimer’s disease at age 54 and progressively deteriorated over the
next ten years, receiving only phenytoin and ampicillin in the months
before dying at age 64. The post-mortem death-to-freezing interval
was 10 h. Patient CBTB 1271 developed Alzheimer’s disease at age
56, but also revealed metastatic adenocarcinoma over the next
6 months. He died at age 57, having taken anti-cancer medication
in the months before death. The post-mortem death-to-freezing inter-
val was 5.5 h. The frozen tissue samples were homogenized by means
of sonication (3 min; Branson) in bu¡er (5 mM Tris-HCl, pH 7.4,
2 mM EDTA, with protease inhibitors as outlined above). The homo-
genate was centrifuged at 500Ug for 10 min. The supernatant was
centrifuged at 50 000Ug for 20 min, resuspended in bu¡er and re-
centrifuged at 50 000Ug for 20 min.
2.3. Photoa⁄nity compounds for labelling dopamine D2 receptors
Two photoa⁄nity compounds were used to label dopamine D2
receptors: [125I]-4-azido-5-iodonemonapride ([125I]A-YM) and N-(p-
azido-m-[125I]iodophenethyl)spiperone ([125I]NA-PS). N-(p-Azido-m-
[125I]iodophenethyl)spiperone has previously been used to photolabel
dopamine D2 receptors [14].
[125I]-4-Azido-5-iodonemonapride was prepared as follows. The
amino compound, 4-normethyl-5-deschloronemonapride (Research
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Biochemical International MH-Y-705), was synthesized and provided
by Drs. R.A. Milius and J.L. Neumeyer (Research Biochemical Inter-
national, Natick, MA, USA). (Nemonapride, formerly known as YM-
09151-2, is ( þ )-cis-N-(1-benzyl-2-methyl-pyrrolidin-3-yl)-5-chloro-2-
methoxy-4-methylaminobenzamide [7,15,16].) Thereafter, 4-normeth-
yl-5-deschloronemonapride (RBI MH-Y-705) was converted to either
the non-radioactive azido compound, 4-azido-5-iodonemonapride (or
RBI MH-Y-704), or to the radioactive photolabel azido compound,
[125I]-4-azido-5-iodonemonapride (known as [125I]azido-MH-Y-705,
catalog No. NEX-084 or NET-999D000MC, lot No. 2903214, cus-
tom-prepared by New England Nuclear Life Science Products, Du-
Pont de Nemours), by means of iodination with chloramine-T.
Both N-(p-azido-m-[125I]iodophenethyl)spiperone and [125I]-4-azido-
5-iodonemonapride were prepared carrier-free, each with a speci¢c
activity of 2200 Ci/mol. Because these radioactive molecules self-de-
struct upon the release of the gamma particle, the molarity decreased
with time, but the speci¢c activity remained constant.
2.4. Photoa⁄nity labelling of D2 receptors expressed in Sf9 cells
Human recombinant dopamine receptors, type 2long, purchased
from Biosignal (Montreal, QueŁ., Canada), had been overexpressed
in baculovirus-infected Spodoptera frugiperda Sf9 insect cells (cultured
in Grace’s medium supplemented with 10% fetal bovine serum). Ali-
quots of Biosignal membranes (25^100 Wg protein) were centrifuged at
14 000 rpm for 5 min at 4‡C (centrifuge 5415C, Brinkmann Instru-
ments, Toronto, Canada). The membrane pellets were washed twice in
50 mM Tris-HCl, pH 7.5, and ¢nally resuspended in 50 mM Tris-HCl
(pH 7.5) at protein concentrations of 3^12 Wg/Wl. To minimize protein
degradation, protease inhibitor cocktail tablets were added according
to Boehringer Mannheim’s speci¢cations.
To label the receptors, the ¢nal concentrations of the radiophoto-
labels were between 0.3 and 20 nM in a ¢nal volume of 35 Wl, con-
taining 50 Wg of rat brain striatal membrane protein. Non-speci¢c
binding was that which occurred in the presence of 100 nM (+)-buta-
clamol or 10 WM S-sulpiride. Protease inhibitor cocktail tablets were
also added according to Boehringer Mannheim’s speci¢cations. The
membranes were incubated in the dark with either 2^6 nM
[125I]A-YM or 2^6 nM [125I]NA-PS at room temperature (22‡C) in
a ¢nal volume of 35 Wl, using a 1-ml plastic conical centrifuge tube.
The samples were then placed on ice, and the tops of the tubes were
exposed to ultraviolet light (365 mW) for 1.5 min. The tubes were
centrifuged at 14 000 rpm for 8 min at 4‡C (centrifuge 5415C; Brink-
mann Instruments). The surfaces of the pellets were rinsed twice with
50 mM Tris-HCl (pH 7.5), and each pellet ¢nally solubilized (one part
pellet to two parts SDS bu¡er) in 35 Wl of SDS bu¡er (50 mM Tris-
HCl, pH 6.8, 10% sodium dodecyl sulfate, 10% glycerol, 5% 2-mer-
captoethanol, 0.05% bromphenol blue) and analyzed by SDS-PAGE
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis). The sam-
ples were loaded onto 10-well, 1.5-mm, 8^16% Tris-glycine gels, and
ran for approximately 2 h at 135 V. Each gel was then incubated with
gentle mixing in 50 ml of methanol/acetic acid (40:18%) for 1.5 h at
22‡C. The gels were dried under vacuum for 1.5 h at 80‡C using a
Bio-Rad model 583 gel dryer. The gels were overlaid with Kodak
Scienti¢c Imaging Film, placed in double-sided high-intensity screen
autoradiography cassettes, and stored at 370‡C for 1^60-day expo-
sures. Films were developed using a Kodak model M35A X-OMAT
diagnostic imaging ¢lm processor. The molecular mass of proteins
was determined using apparent molecular weights from the pre-
stained protein marker Superblue 2360.
2.5. Immunoblot analysis
After completing the SDS-PAGE procedure, the samples were
transferred onto a nitrocellulose membrane (0.2 Wm), using 30 V for
2.5 h. The nitrocellulose membrane was blocked for 1 h with 5% skim
milk powder and 1.5% bovine serum albumin in Tween 20/Tris-bu¡-
ered saline (TTBS: 0.1% Tween 20, 100 mM Tris-HCl, pH 7.5, and
0.9% NaCl). Once blocked, the nitrocellulose membrane was washed
for 1 h in Tris-bu¡ered saline (TBS: 100 mM Tris-HCl, pH 7.5, and
0.9% NaCl) and then incubated overnight at 4‡C with the AL-26
polyclonal primary antibody dissolved in TBS (1:1000 dilution).
This antibody is directed against a 120-amino acid sequence (N-ter-
minus 661^1020) in the third intracellular loop of the human D2long
receptor [17]. The immunoblot was then washed for 1 h in TTBS,
followed by incubation for 3 h at 22‡C with a secondary antibody,
protein [125I]protein-A (¢nal concentration of 1 WCi/ml; New England
Nuclear Life Science Products, DuPont de Nemours, Boston, MA,
USA), dissolved in TBS (1:5000 dilution). The immunoblotted nitro-
cellulose membrane was then exposed to Kodak Imaging ¢lm using
double-sided high-intensity screens for 1^3 days at 370‡C and devel-
oped as described above.
3. Results
Because earlier work on bovine and pig tissues had not
detected D2 dimers [18], while later work on cloned and
highly expressed D2 receptors did detect dimers [11^13], we
thought it essential to enrich the D2 receptors in order to
detect D2 dimers in rat brain striatum. The result is shown
in Fig. 1, where 6 nM [125I]azidophenethylspiperone detected
only the glycosylated monomer of D2 at 120 kDa (lane 1),
while [125I]-4-azido-5-iodonemonapride detected both the
monomer and the dimer (V250 kDa) of the D2 receptor
(lane 3). (The high concentration of 6 nM was chosen to
ensure that most of the receptors would be occupied by
each radiophotolabel, because the dissociation constant of
4-azido-5-iodonemonapride (RBI MH-Y-704) was 0.46 nM
on human cloned dopamine D2 receptors, using 250 pM
[3H]spiperone to label these receptors (unpublished), and be-
cause the dissociation constant of [125I]azidophenethylspiper-
one was also of the same order of magnitude [12] as 4-azido-
5-iodonemonapride.)
The results in Fig. 1 for rat brain striatum are similar to
those for human cloned D2 receptors expressed in insect Sf9
cells, as shown in Fig. 2. This Fig. 2 contains additional con-
trol data, indicating that the photolabelling by [125I]-4-azido-
5-iodonemonapride was stereoselectively blocked by (+)-buta-
clamol and not by (3)-butaclamol (lanes 2 and 3), and that
the Sf9 cells alone (i.e. not expressing D2 receptors) were not
photolabelled in the regions of 125 and 250 kDa (lanes 6 and
7).
Fig. 3 illustrates two examples of results on post-mortem
human caudate nucleus tissue from individuals who had Alz-
heimer’s disease. The example on the left in Fig. 3 shows that
[125I]azidophenethylspiperone primarily labelled the D2 mono-
mer in brain CBTB 1271, and the labelling was occluded by
4 WM (+)-butaclamol. In the example shown on the right in
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Fig. 1. Dopamine D2 receptors in rat brain striatal membranes were
photolabelled with 6 nM [125I]azidophenethylspiperone ([125I]NA-PS)
or 6 nM [125I]-4-azido-5-iodonemonapride ([125I]A-YM), subjected to
SDS-PAGE, and exposed to Kodak imaging ¢lm. The glycosylated
monomer of D2, with an MW of V120 kDa, was photolabelled by
[125I]NA-PS (lane 1) and by [125I]A-YM (lane 3). However, only
[125I]A-YM labelled the D2 dimer, with an MW of V250 kDa, as
shown in lane 3. Non-speci¢c binding was that which occurred in
the presence of 10 WM S-sulpiride.
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Fig. 3 for brain CBTB 355, [125I]-4-azido-5-iodonemonapride
primarily labelled D2 dimers. We were not able to determine
what biochemical factors or variables in the procedure would
lead to a preponderance of dimers for either human or rat
brain striatal tissues.
In order to obtain evidence for the existence of D2 dimers
by means of another method, human cloned D2 receptors,
expressed in insect Spodoptera frugiperda cells, were immuno-
blotted and probed with the D2-speci¢c antibody AL-26, the
results of which are shown in Fig. 4. This ¢gure reveals bands
for [125I]protein-A at V55 kDa, V110 kDa, V158 kDa,
V221 kDa, and V347 kDa, suggesting the existence of not
only monomers and dimers of D2, but also trimers, tetramers
and pentamers of D2, compatible with the concept of higher
order oligomers for seven-transmembrane-G-linked receptors
[19,20].
4. Discussion
Figs. 1 and 2 indicate that D2 dimers can occur in rat brain
striatal membranes as well as in human cloned D2 receptors.
As monitored by photoa⁄nity labelling, the proportion of
dimers is at least 1^5% of the monomer fraction, as indicated
by the relative intensities shown in Figs. 1 and 2. The propor-
tion may be much higher than 1^5%, because the photoa⁄n-
ity labelling procedure may result in a low total number of
receptors to become labelled.
The immunoblot data (Fig. 4) provided more evidence for
the existence of D2 dimers, while also indicating the existence
of trimers, tetramers and pentamers of D2. The [125I]protein-
A bands in Fig. 4 correspond to the appropriate molecular
weights of D2 monomers (V48 kDa) and dimers (V98 kDa),
as predicted by the receptor’s amino acid sequence.
Many signal transducing receptors, including growth factor
receptors and cytokine receptors, depend on the formation of
dimers for proper function. For example, disruption of dimers
of the L-adrenoceptor inhibits its function [21]. Receptor
dimers may also regulate desensitization, endocytosis, and re-
cycling of receptors. Agonist exposure may increase or de-
crease the dimer:monomer ratio [21,22], while inverse agonists
decrease this ratio [21], suggesting that interconversion be-
tween monomers and dimers may be important for biological
activity. It will be essential to examine these physiological
processes for D2 receptors in health and disease. For example,
it is possible that there may be a monomer-dimer imbalance in
dopaminergic diseases such as schizophrenia.
The data in Fig. 4 suggest the existence of additional higher
order oligomers, namely, trimers, tetramers and pentamers.
However, since protein-A can also bind non-speci¢cally to
IgG molecules, it is also possible that these bands may repre-
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Fig. 4. Human cloned dopamine D2 receptors immunoblotted with
D2 antibody and [125I]protein-A. D2 receptors (expressed in insect
Sf9 cells) were subjected to SDS-PAGE (25 Wg protein per lane),
immunoblotted with a D2-speci¢c antibody, and detected with
[125I]protein-A (1 WCi/ml). Control samples, containing wild-type Sf9
cells (transfected with baculovirus, but not expressing D2 receptors)
did not show any immunoreactive bands.
Fig. 3. Dopamine D2 receptors in post-mortem human brain cau-
date nucleus membranes were photolabelled with 10 nM [125I]-4-azi-
do-5-iodonemonapride ([125I]A-YM) or 20 nM [125I]azidophenethyl-
spiperone ([125I]NA-PS), subjected to SDS-PAGE, and exposed to
Kodak imaging ¢lm. Left: Brain CBTB 1271 (Alzheimer’s disease):
the glycosylated monomer of D2, with an MW of V100 kDa, was
photolabelled by [125I]NA-PS with a faint band appearing at V200
kDa (lane 1), both bands of which did not appear in the presence
of 4 WM (+)-butaclamol (lane 2). Right: Brain CBTB 355 (Alzheim-
er’s disease): although the monomer of D2, with an MW of V100
kDa, did not appear here with [125I]A-YM, the dimer band of
V200 kDa (lane 3) did appear, this band not showing in the pres-
ence of 4 WM (+)-butaclamol (lane 4).
Fig. 2. Human cloned dopamine D2 receptors photolabelled with
6 nM [125I]-4-azido-5-iodonemonapride ([125I]A-YM), subjected to
SDS-PAGE, and exposed to Kodak imaging ¢lm. Non-speci¢c bind-
ing was de¢ned as that occurring in the presence of 100 nM (+)-bu-
taclamol.
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sent other proteins expressed within the cell but which are not
related to dopamine D2 receptors.
An important observation in Fig. 1 is that [125I]azidophen-
ethylspiperone only labelled the rat brain D2 monomer,
while [125I]-4-azido-5-iodonemonapride labelled both the D2
monomers and dimers, despite the fact that very high concen-
trations (6 nM) of both radiocompounds were used. These
data suggest that the spiperone and benzamide congeners
may label di¡erent populations of the D2 receptor, possibly
resolving the density discrepancies found with these two ra-
dioligands in positron tomography [1^6]. In other words, be-
cause the benzamide attaches to both monomers and dimers,
the density of [11C]raclopride sites would be expected to ex-
ceed the density of D2 monomer sites labelled by
[11C]methylspiperone, as is the case (see Section 1).
The apparent selectivity of [125I]azidophenethylspiperone to
detect monomers of D2 but not dimers or higher order
oligomers may be attributed to ‘negative cooperativity’. This
mechanism of negative cooperativity as the basis for multiple
states of receptor a⁄nity has been previously applied to the
cardiac muscarinic receptor [19,23]. These latter studies sug-
gested that negative cooperativity may explain di¡erences in
the relative receptor densities observed with two di¡erent
muscarinic radioligands. Hence, receptor oligomers may also
explain why di¡erent radioligands yield di¡erent densities for
the G protein-coupled D2 receptor [8]. Moreover, negative
cooperativity between receptors in oligomeric species may re-
sult in decreased a⁄nity towards speci¢c ligands.
Although the D2 antibody was capable of detecting higher
order oligomers of D2, the [125I]-4-azido-5-iodonemonapride
was not able to detect them. It is possible, therefore, that the
structural conformation of the D2 receptor in these oligomeric
states may make the binding pocket inaccessible to the photo-
label, while not interfering with the binding sites for the anti-
body.
The present experiments observed D2 receptor monomers,
dimers, and higher order oligomers by means of SDS-PAGE.
The results only reveal receptor species that are resistant to
the detergent SDS. In the absence of disul¢de bonds, the
oligomeric forms of the receptor must be held together by
strong inter- and intramolecular forces, as predicted by Mag-
gio et al. [24]. However, the low proportion of dimers, com-
pared to the abundance of monomers in the photolabel ex-
periments (but not in the [125I]protein-A data) suggests that
the SDS-PAGE method may disrupt the dimer form of the
receptor.
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